Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Full results from Phase 3 study for presbyopia-correcting eye drop ➤ Cells from two donors treat dozens of patients with corneal endothelial disease ➤ Study: Dry eye treatment reduces halos after cataract surgery ➤ NDA accepted for IND application for novel, investigational dry eye drug ➤ Acquisition of ophthalmic drug candidate ➤ ASCRS events
➤ FDA grants IDE for MIGS device to start pivotal trial ➤ Breakthrough therapy designation granted for possible Stargardt treatment ➤ Refractive surgery uptick continues ➤ First patient dosed in trial for light-activated optogenetic monotherapy for RP ➤ Diagnostic device company acquires ophthalmic device manufacturer ➤ Two ophthalmic companies partner ➤ ASCRS news and events
➤ New visual prosthesis heads to clinical trial ➤ FDA grants Fast Track designation to investigational wet AMD therapy ➤ Patient enrollment complete in Phase 3 trial for investigational, first-in-class eye drop for DED ➤ FDA agrees to pivotal trial design for investigational treatment of geographic atrophy secondary to AMD ➤ ASCRS news and events
➤ Combination pharmaceutical therapy being investigated for presbyopia meets study endpoints ➤ Positive results in Phase 2 clinical trial for IOP-lowering agent ➤ Phase 3 results from study of gene therapy for retinal neurodegenerative diseases ➤ Positive safety results in Phase 1 anti-VEGF treatment ➤ ASCRS news and events
➤ FDA approves drops for vernal keratoconjunctivitis ➤ Data from investigational first-in-class dry eye therapy ➤ FDA accepts BLA for Port Delivery System of ranibizumab ➤ Companies enter collaboration to investigate treatments for dry AMD ➤ ASCRS news and events
➤ Survey: 96% of ophthalmologists vaccinated against COVID-19 ➤ Phase 2b/3 results from trial for Demodex blepharitis ➤ Data from ongoing Phase 2a study of therapy for geographic atrophy ➤ First patient enrolled in Phase 2 study of nasal spray for neurotrophic keratopathy ➤ Next ASCRS Journal Club on July 8
➤ Investigational gene therapy for choroideremia does not meet study endpoints ➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD ➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant ➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies ➤ ASCRS events
➤ Results from Phase 1 clinical trial of intranasal glaucoma drug ➤ Phase 3 clinical trial of new ophthalmic corticosteroid nanoemulsion ➤ Pharmaceutical company expands gene therapy pipeline ➤ Companies enter agreement to develop next-generation decision support software ➤ Study: Association between caffeine intake and glaucoma
➤ Early termination of study evaluating Beovu ➤ NDA resubmitted to FDA for investigational macular edema treatment ➤ First peer-reviewed paper on visual recovery in a blind patient treated with optogenetic therapy ➤ Study: New riboflavin formulation enhances transepithelial crosslinking ➤ Enrollment complete for blepharitis trial ➤ Companies partner to develop human-induced pluripotent stem cell-derived therapies for ocular diseases ➤ ASCRS events
➤ Positive topline results in Phase 3 study for temporary presbyopia therapy ➤ Study: New therapy for ocular infections ➤ Analysis of more than half a million cataract surgeries yields PCO insights ➤ Patients blinded from AMD benefit from visual prosthetic ➤ New company focuses on refractive pharmaceutical treatments ➤ ASCRS events
Get the latest ophthalmology news delivered to your inbox every Friday.